From the generics industry perspective, and again from an Apotex perspective, any drug shortage is an issue. I would say, however, that one thing we have to learn from this pandemic is this: Strengthen our domestic manufacturing capabilities. Canada is 2% to 3% of the global pharmaceutical market. My key message today is that we need to learn from COVID-19. What happened around the world was that there were restrictions on exports.
I can tell you that what gets me out of bed in the morning, as it does all of my colleagues, is the patient dealing with anxiety, depression, cardiovascular illness or oncology. We go to work every day to make sure there's a continuity of therapy for Canadians. We need to make sure. A lot of the manufacturing has left this country.
In terms of what Apotex produces, almost 80% of all the drugs we sell are manufactured in Ontario for Canadians. I can tell you two stories. There was a global shortage of tamoxifen. Were it not for our facilities in Canada.... We actually reprioritized all of our production schedule for Canadians. No one's doing—